Allarity Therapeutics Secures 11-Year Patent Extension for Stenoparib Diagnostic, Advances Cancer Trials
ALLR sits 85% above its 52-week low of $0.769.
Summary
Allarity Therapeutics reported its first-quarter 2026 results, highlighting a strong cash position of approximately $29.8 million and a lower net loss per share compared to the prior year. Crucially, the company announced a Notice of Allowance for a U.S. patent application covering its stenoparib-specific DRP® companion diagnostic, which is expected to extend exclusivity for the drug by at least 11 years. This is a significant intellectual property win for the company's lead asset. Furthermore, clinical development for stenoparib is progressing, with a new VA-funded Phase 2 trial initiated for relapsed small cell lung cancer and continued enrollment in the FDA Fast Track designated advanced ovarian cancer trial. The Phase 3 manufacturing campaign is also on track, and new preclinical data was presented at AACR 2026. These operational and IP advancements significantly de-risk stenoparib and provide a strong positive catalyst for the company.
At the time of this announcement, ALLR was trading at $1.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21.4M. The 52-week trading range was $0.77 to $2.35. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.